Benzinga | Aug 30, 2021 09:00AM EDT

FDA Grants Lantern Pharma Additional Orphan Drug Designation For Drug Candidate LP-184 In Glioblastoma Multiforme & Malignant Gliomas

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation (ODD) for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas. This news follows the recent announcement of the FDA granting LP-184 ODD for the treatment of pancreatic cancer.